- IN₹276.56bn
- IN₹249.20bn
- IN₹56.17bn
- 97
- 17
- 57
- 62
Annual balance sheet for Gland Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 30,058 | 32,427 | 37,628 | 19,388 | 29,522 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,188 | 13,599 | 11,381 | 18,908 | 20,581 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 51,236 | 58,521 | 69,008 | 56,452 | 67,829 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 12,920 | 16,804 | 17,361 | 38,302 | 39,439 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 64,961 | 78,336 | 87,775 | 106,612 | 112,249 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5,125 | 5,820 | 7,291 | 13,984 | 15,648 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5,928 | 6,760 | 8,188 | 19,374 | 20,742 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 59,032 | 71,576 | 79,587 | 87,238 | 91,507 |
| Total Liabilities & Shareholders' Equity | 64,961 | 78,336 | 87,775 | 106,612 | 112,249 |
| Total Common Shares Outstanding |